Here are the DEF 14A proxy statements from Avita Medical, Inc. (RCEL) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow RCEL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RCEL filings page.
AVITA Medical, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 3, 2026. Investors will elect seven directors, ratify Grant Thornton LLP as auditor for 2026, and increase the non-executive director cash fee pool from US$750,000 to US$900,000.
Stockholders are also asked to approve multiple grants of restricted stock units and options to non-executive directors, advisory votes on executive pay and its frequency, issuance of warrants covering up to 650,000 shares to Perceptive Credit Holdings V, LP, and authority to issue additional equity securities up to 10% of issued capital under ASX rules.